SkinBioTherapeutics (LON:SBTX) Shares Down 0.7% – Should You Sell?

SkinBioTherapeutics plc (LON:SBTX)’s share price traded down 0.7% during mid-day trading on Tuesday . The company traded as low as GBX 9.25 and last traded at GBX 9.25. Approximately 18,460 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 2,575,959 shares. The stock had previously closed at GBX 9.31.

SkinBioTherapeutics Price Performance

The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01. The firm has a market capitalization of £23.97 million, a P/E ratio of -57.80 and a beta of 0.11. The firm’s 50 day simple moving average is GBX 10.50 and its two-hundred day simple moving average is GBX 9.87.

SkinBioTherapeutics (LON:SBTX) last issued its earnings results on Monday, June 8th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. SkinBioTherapeutics had a negative return on equity of 5.25% and a negative net margin of 8.73%.The firm had revenue of GBX 217 million during the quarter.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.